And that's one thing we learned from the work of the task force is, you know, as public policymakers and regulators, it's difficult to understand where to focus on the supply chain. Everyone's pointing fingers at everyone else. There's a lack of information, there's a lack of transparency [in the drug pricing and supply chain system]. And one of the things that we learn through that process is having more transparency, more disclosure, more reporting, just more understanding of how that whole drug pricing, drug supply … (31:44–31:59)
CLAIM
Asserts that there is insufficient information and transparency in the drug pricing and supply chain system.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
